by Annabel Sedgwick
Share
by Annabel Sedgwick
Share
Following the creation of a successful distribution partnership with Medworks to supply the Galaxy range to urology and gynecology surgery markets across several states, JUNE Medical is now rapidly expanding the availability of this popular range by recruiting a direct sales network to supply other states and additional surgical specialties.
Medworks is already supplying the Galaxy range to the urology and gynecology surgery markets through its extensive hospital client base. Darrell Shires, president of Medworks commented: “We are extremely pleased to have partnered with JUNE Medical on its Galaxy range. Because of our expertise as a technology supplier in urology and gynecology, the Galaxy products have fitted seamlessly into our portfolio, and we are now supplying them to numerous hospitals.”
Angela Spang, CEO of JUNE Medical, commented: “We are delighted to have Darrell and Medworks on board with us, helping JUNE Medical to expand the use of its innovative surgical products in the US market. Our aim is now to expand our network of distribution partnerships and direct sales to supply the Galaxy II to surgeons in every state.”
Visit the JUNE Medical (www.galaxyretractor.com) or the Medworks (www.medworkssurgical.com) websites to learn more.
About JUNE Medical Group
JUNE Medical Group is an award winning medical device distributor with offices in the UK, USA and Sweden. Galaxy II self retaining retractor.
Microban® International – the global leader in antimicrobial additives and odor control solutions – has released a statement discrediting unwarranted claims about the safety and efficacy of antimicrobial technologies. This statement is intended to ensure that the public, consumers, and other stakeholders are equipped to make fully informed decisions, based on scientific reasoning. Making a clear distinction between public health and non-public health claims, Microban has explained the advantages of incorporating its antimicrobial additives into
Anion dysregulation is seen in numerous diseases, from cystic fibrosis and chronic pain, to autism and cancer. Researchers at the University of Dallas are investigating anion transport in vivo, developing novel tools to help analyze the effects of both normal and aberrant anion regulation at the molecular level, and are using INTEGRA’s PIPETBOY acu 2 to streamline their cell
June Medical is one of 48 organisations to be recognised for their excellence in innovation in this year’s Queen’s Awards for Enterprise. Now in its 55th year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country – rewarding only the most outstanding achievements – with winning businesses able to use the esteemed
A report from the International Agency for Research on Cancer1 recently classified TiO2 as ‘possibly carcinogenic to humans’ by inhalation and similarly, the European Chemicals Agency2 recommended TiO2 be classified as a category 2 carcinogen (suspected of causing cancer). In contrast, antimicrobial technologies from Microban International are based on SilverShield®, the first patented antimicrobial solution